L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells

被引:0
|
作者
E Ayroldi
M G Petrillo
A Bastianelli
M C Marchetti
S Ronchetti
G Nocentini
L Ricciotti
L Cannarile
C Riccardi
机构
[1] Section of Pharmacology,Department Medicine
[2] University of Perugia Medical School,undefined
来源
Cell Death & Differentiation | 2015年 / 22卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The transcription factor p53 regulates the expression of genes crucial for biological processes such as cell proliferation, metabolism, cell repair, senescence and apoptosis. Activation of p53 also suppresses neoplastic transformations, thereby inhibiting the growth of mutated and/or damaged cells. p53-binding proteins, such as mouse double minute 2 homolog (MDM2), inhibit p53 activation and thus regulate p53-mediated stress responses. Here, we found that long glucocorticoid-induced leucine zipper (L-GILZ), a recently identified isoform of GILZ, activates p53 and that the overexpression of L-GILZ in p53+/+ HCT116 human colorectal carcinoma cells suppresses the growth of xenografts in mice. In the presence of both p53 and MDM2, L-GILZ binds preferentially to MDM2 and interferes with p53/MDM2 complex formation, making p53 available for downstream gene activation. Consistent with this finding, L-GILZ induced p21 and p53 upregulated modulator of apoptosis (PUMA) expression only in p53+/+ cells, while L-GILZ silencing reversed the anti-proliferative activity of dexamethasone as well as expression of p53, p21 and PUMA. Furthermore, L-GILZ stabilizes p53 proteins by decreasing p53 ubiquitination and increasing MDM2 ubiquitination. These findings reveal L-GILZ as a regulator of p53 and a candidate for new therapeutic anti-cancer strategies for tumors associated with p53 deregulation.
引用
收藏
页码:118 / 130
页数:12
相关论文
共 50 条
  • [31] mdm2/p53与肿瘤
    金永丽
    王靖华
    陈龙邦
    临床肿瘤学杂志, 2007, (06) : 469 - 471
  • [32] p53和mdm2基因
    沈行良
    翁启芳
    中国热带医学, 2007, (01) : 103 - 105
  • [33] Regulation of p53 stability by Mdm2
    Michael H. G. Kubbutat
    Stephen N. Jones
    Karen H. Vousden
    Nature, 1997, 387 : 299 - 303
  • [34] Mdm2: p53's lifesaver?
    Shmueli, Ayelet
    Oren, Moshe
    MOLECULAR CELL, 2007, 25 (06) : 794 - 796
  • [35] Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry
    Nenutil, R
    Smardova, J
    Pavlova, S
    Hanzelkova, Z
    Muller, P
    Fabian, P
    Hrstka, R
    Janotova, P
    Radina, M
    Lane, DP
    Coates, PJ
    Vojtesek, B
    JOURNAL OF PATHOLOGY, 2005, 207 (03): : 251 - 259
  • [36] MDM2, MDMX and p53 in oncogenesis and cancer therapy
    Mark Wade
    Yao-Cheng Li
    Geoffrey M. Wahl
    Nature Reviews Cancer, 2013, 13 : 83 - 96
  • [37] Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2
    Unger, T
    Juven-Gershon, T
    Moallem, E
    Berger, M
    Sionov, RV
    Lozano, G
    Oren, M
    Haupt, Y
    EMBO JOURNAL, 1999, 18 (07): : 1805 - 1814
  • [38] MDM2, MDMX and p53 in oncogenesis and cancer therapy
    Wade, Mark
    Li, Yao-Cheng
    Wahl, Geoffrey M.
    NATURE REVIEWS CANCER, 2013, 13 (02) : 83 - 96
  • [39] NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
    Liu, Xiaofeng
    Tan, Yuqin
    Zhang, Chunfeng
    Zhang, Ying
    Zhang, Liangliang
    Ren, Pengwei
    Deng, Hongkui
    Luo, Jianyuan
    Ke, Yang
    Du, Xiaojuan
    EMBO REPORTS, 2016, 17 (03) : 349 - 366
  • [40] p53 and MDM2 in the development and progression of bladder cancer
    SchmitzDrager, BJ
    Kushima, M
    Goebell, P
    Jax, TW
    Gerharz, CD
    Buttel, H
    Schulz, WA
    Ebert, T
    Ackermann, R
    EUROPEAN UROLOGY, 1997, 32 (04) : 487 - 493